Clinical Trial Update: A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating BBI608 or BBI503 in combination with sorafenib in adults with hepatocellular carcinoma has completed, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BBI503
• BBI608
• Sorafenib (Sorafenib)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-09